New drug AB801 takes first steps against advanced cancers

NCT ID NCT06120075

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 27 times

Summary

This study tests a new drug called AB801, alone or with other treatments, in about 91 people with advanced cancers like lung, colon, breast, or ovarian cancer that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose. This is an early-stage trial, so it focuses on side effects and how the drug moves through the body, not on curing the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Denver, Colorado, 80218, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Grand Rapids, Michigan, 49546, United States

  • Research Site

    New York, New York, 10128, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Dallas, Texas, 75230, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    West Valley City, Utah, 84119, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.